Join

or

Existing user? Login

Asthma

No significant difference between LAMAs and LABAs in treating persistent asthma, research finds

Data from 15 randomised trials show that while long-acting muscarinic antagonists reduced exacerbation risk by a third, there was no significant improvement compared with long-acting beta-agonists.

Asthma inhaler, salmeterol, long acting beta agonists (LABA)

Source: Science Photo Library

Study found no significant difference between LABAs and LAMAs in preventing asthma exacerbations 

Long-acting beta-agonists (LABAs), such as salmeterol, are currently the primary add-on therapy for patients with persistent asthma. However, the comparative efficacy of long-acting muscarinic antagonists (LAMAs), such as tiotropium bromide, is less clear.

To explore, researchers carried out a systematic review and meta-analysis of 15 randomised trials comparing a LAMA with placebo or a LABA, as add-on therapy to inhaled corticosteroids (ICS) in 7,122 patients with persistent asthma[1].

The data show that LAMAs reduced the risk of exacerbations requiring systemic corticosteroids by 33% and asthma worsening by 19%, compared with placebo, but there was no significant improvement compared with LABA therapy. The researchers also discovered that triple therapy (ICS+LABA+LAMA) provided no additional benefit over ICS+LABA with regards to exacerbation risk.

Reporting in JAMA (online, 19 March 2018), the researchers said the current evidence does not suggest a significant difference between LABAs and LAMAs in preventing exacerbations but further studies are needed to determine if either is superior.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204704

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50
  • BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50
  • Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00
  • Introduction to Statistics in Pharmaceutical Clinical Trials

    An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.

    £38.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Supplementary images

  • Asthma inhaler, salmeterol, long acting beta agonists (LABA)

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

аминокислоты

www.adulttorrent.org

topobzor.info/tag/umi/